A Phase I, Open, Mono-center and Dose Escalation Study Investigating Tolerance and Pharmacokinetics of Single and Multiple Doses of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Injection in Patients With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase I, Open, Mono-center and Dose Escalation Study Investigating Tolerance and Pharmacokinetics of Single and Multiple Doses of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Injection in Patients With Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Apr 2018

At a glance

  • Drugs JS 001 (Primary)
  • Indications Malignant melanoma; Renal cell carcinoma; Solid tumours; Urogenital cancer
  • Focus Adverse reactions
  • Sponsors Shanghai Junshi Biosciences

    • Most Recent Events

    • 26 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Mar 2018.
    • 06 Nov 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Dec 2017.
    • 27 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top